Pliant Therapeutics (PLRX) shares fell 60% in recent Monday trading after several investment firms downgraded their ratings on the company following its announcement late Friday that it has suspended enrollment and dosing in a phase 2b trial of bexotegrast for idiopathic pulmonary fibrosis.
RBC downgraded Pliant to sector perform from outperform and cut its price target to $4 from $45, Oppenheimer downgraded the company to perform from outperform, HC Wainwright downgraded it to neutral from buy, Citigroup downgraded it to neutral from buy, with a $4 price target, and Wells Fargo downgraded it to equalweight from overweight, with a $4 price target.
Price: 3.09, Change: -4.70, Percent Change: -60.36
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.